DIRS.INFO The most relevant business & tech news

☆ Planning for retirement? These stocks make 'great long-term investments,' according to the pros
▼ + stars: | 2024-06-18 | by ( Weizhen Tan | ) www.cnbc.com time to read: +5 min

But investors with a greater risk appetite or a longer runway to retirement can consider stocks. CNBC Pro asked the experts what stocks they would buy that are suited to long-term investing for retirement purposes. Dziubinski named three stocks which she says look undervalued but will make "great long-term investments" at current prices. Starbucks Dziubinski says Starbucks ' brand and pricing power have earned it a wide economic moat rating, which according to the firm refers to a company's durable competitive advantage. Wheaton Precious Metals Regal Point Capital's Marolia named Wheaton Precious Metals as a stock with long-term potential.

Persons: Susan Dziubinski, Dziubinski, Vijay Marolia, Morningstar, Marolia, it's, Wheaton, we've, we're Organizations: Morningstar, CNBC Pro, Regal Point, Consumer, Johnson, Brands, Nike Nike, Nike, Wheaton Precious, Wheaton Precious Metals, Blackstone Group

☆ 4 cheap stocks to buy and hold for the next decade, according to the pros
▼ + stars: | 2024-04-12 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

Many shares look expensive in today's market, but there are still cheap stocks to be found — some of which can be held for the next 10 years, according to the pros. They shared with CNBC Pro their tips for picking cheap stocks that hold long-term promise, as well as their top picks. How to pick cheap stocks Morningstar's Susan Dziubinski says she believes in owning stocks that offer "some sense of certainty" in terms of cash flow and company fundamentals. Freddie Lait, chief investment officer at Latitude Investment Management, says a willingness to invest in some cyclical stocks is key. Cheap stocks to hold for the long term Morningstar's Dziubinski named three cheap stocks that investors can hold for the next decade: U.S. consumer health firm Kenvue , regional U.S. bank U.S. Bancorp , and medical equipment firm Zimmer Biomet .

Persons: Susan Dziubinski, isn't, Freddie Lait, Lait, he's, Dziubinski, Zimmer Biomet, Morningstar, Bancorp Morningstar, AutoZone Organizations: CNBC, Latitude Investment Management, U.S . Bancorp, Companies, Bancorp Locations: U.S, AutoZone

☆ Cramer's Lightning Round: Essential Utilities is at 'a good place to buy'
▼ + stars: | 2023-09-14 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Kenvue's year-to-date stock performance. Stock Chart Icon Stock chart icon UiPath's year-to-date stock performance. Stock Chart Icon Stock chart icon Essential Utilities' year-to-date stock performanceEssential Utilities : "I like them...It's very cheap right now, it's actually a good place to buy." Stock Chart Icon Stock chart icon Plug Power's year-to-date stock performance. Stock Chart Icon Stock chart icon Roku's year-to-date stock performance.

Persons: Abbott, It's, they're, it's, We've, Jim Cramer's Organizations: Utilities

☆ Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer
▼ + stars: | 2023-07-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson on Monday said it plans to reduce by at least 80% its stake in Kenvue, the consumer health business it spun out as an independent company earlier this year, via a stock exchange offer. J&J owns 89.6% of Kenvue's common stock, which amounts to more than 1.72 billion shares. The exchange offer, also known as a split-off, will allow J&J shareholders to swap all or a portion of their shares for Kenvue's common stock at a 7% discount. J&J first announced its intent to launch an exchange offer in its second-quarter earnings report on Thursday, but the company provided few details on the plan. When asked about J&J's planned exchange offer on Thursday, Kenvue CEO Thibaut Mongon told CNBC's "Squawk on the Street" that the company is "pleased with the way that the IPO has been received by shareholders."

Persons: Johnson, J, Joaquin Duato, Duato, Kenvue, J's, Thibaut Mongon, CNBC's Organizations: J Locations: Kenvue

☆ Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
▼ + stars: | 2023-07-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Most consumers have pulled back on spending as inflation squeezes their wallets, but they have not stopped paying up for brand-name health and personal care products, Kenvue CEO Thibaut Mongon said. Kenvue also noted that "private label" penetration in the consumer health product market was stable for the quarter. Those spending trends could bode well not only for Kenvue, but also for other companies in the consumer health, beauty and beverage spaces that may not see consumers trade down to cheaper products as often despite stubbornly high prices. RBC Capital analyst Nik Modi expressed confidence in Kenvue's ability to "maintain its momentum," highlighting consumer trust in the company's brands and health and personal care products overall. Meanwhile, Kenvue has gained market share, and could potentially continue to do so despite the broader environment, he noted.

Persons: Thibaut Mongon, Johnson, Mongon, Kenvue, bode, we've, Nik Modi, Modi Organizations: Kenvue Inc, New York Stock Exchange, CNBC, Johnson, J, RBC Capital Locations: Kenvue

☆ Kenvue earnings top estimates in J&J spinoff's first quarterly report since IPO
▼ + stars: | 2023-07-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Kenvue reported second-quarter revenue and adjusted earnings that topped expectations Thursday in the consumer health company's first quarterly report since it spun out from Johnson & Johnson two months ago. But J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the spinoff's business for now. Excluding certain items, the company's adjusted earnings were 32 cents a share. The company's full-year adjusted earnings outlook is $1.26 to $1.31 per share. The company reported sales growth across its three business divisions in the second quarter.

Persons: Kenvue, Johnson, Kenvue's, Thibaut Mongon, headwinds, Mongon Organizations: Johnson, Refinitiv, Deutsche Bank Global Consumer Conference Locations: Kenvue, Canada

☆ Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know
▼ + stars: | 2023-07-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson on Thursday said its shareholders will soon be able to swap their shares for stock of Kenvue , which spun out as an independent consumer health company just two months ago. That process, also known as a split-off, will allow J&J shareholders to exchange all or a portion of their shares for Kenvue's common stock. Kenvue shares fell following the announcement Thursday, even though the company beat earnings and revenue estimates in its first quarterly report since its IPO. Previously, J&J did not disclose whether it would divest its Kenvue shares through a split-off or a spinoff. The latter would involve distributing Kenvue stock to existing J&J shareholders rather than giving them the option to exchange.

Persons: Thibaut Mongon, Paul Ruh, Johnson, J, Joseph Wolk, Wolk, J's, CNBC's, Kenvue, Goldman Sachs, JPMorgan Chase Organizations: Kenvue Inc, New York Stock Exchange, JPMorgan Locations: New York City, U.S

☆ J&J-spinoff Kenvue forecasts upbeat annual profit on strong self-care demand
▼ + stars: | 2023-07-20 | by ( ) www.reuters.com time to read: +2 min

Companies Kenvue Inc FollowNeutrogena Corporation FollowHaleon Plc Follow Show more companiesJuly 20 (Reuters) - Kenvue (KVUE.N), the former consumer health unit of Johnson & Johnson (JNJ.N), forecast full-year profit above Wall Street estimates on Thursday, betting on resilient demand for its skincare and self-care products such as Neutrogena and Tylenol. Kenvue, in its first results after being spun off from Johnson & Johnson in May, forecast full-year adjusted profit per share between $1.26 and $1.31. However, adjusted gross profit margin came in at 57.5%, compared to 59.3% a year earlier, dragged by a strong dollar and higher costs. Meanwhile, J&J raised its 2023 profit forecast on Thursday, banking on the strength in its medical devices business and demand for its cancer drugs such as Darzalex. Net sales rose 5.4% to $4.01 billion while adjusted profit per share came in at 32 cents.

Persons: Johnson, Haleon, J, Ananya Mariam Rajesh, Raghav, Devika Syamnath Organizations: Johnson, Wall, Thomson Locations: Bengaluru

☆ J&J's strong quarter was amplified by new details around its big Kenvue consumer unit stake
▼ + stars: | 2023-07-20 | by ( Zev Fima | ) www.cnbc.com time to read: +12 min

Johnson & Johnson (JNJ) reported strong second - quarter profit and revenue before the opening bell Thursday, with better-than-expected results both domestically and internationally, as well as across all major operating segments. It's possible that J & J management will offer up Kenvue shares at a discount to market value. Regardless, arbitrage isn't our game and we want to be invested in J & J for the long term. The only change — since J & J owns 89.6% of Kenvue — is that 10.4% of earnings generated since Kevnue went public in early May to the end of the quarter are no longer attributed to J & J. A Johnson & Johnson building is shown in Irvine, California.

Persons: Johnson, —, Kevnue, J, J's, prioritization, Jim Cramer's, Jim Cramer, Jim, Mike Blake Organizations: Dow, Pharmaceutical, Management, J's, Johnson, J, Consumer, Consumer Health, Pharmaceutical Pharmaceutical, CNBC, & $ Locations: Kenvue, JNJ, KVUE, Spravato, Irvine , California

☆ Kenvue CEO looks to brand, product innovation to drive growth after IPO
▼ + stars: | 2023-05-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson consumer-health business, speaks during an interview with CNBC during his company's IPO at the New York Stock Exchange (NYSE), May 4, 2023. Kenvue CEO Thibaut Mongon is betting on brand and product innovation to drive growth at the newly spun-out company after its solid debut on the public market Thursday. Kenvue, spun out of Johnson & Johnson , carries a packed portfolio of widely known brands, such as Band-Aid, Tylenol, Listerine, Neutrogena, Aveeno and J&J's namesake baby powder. But Mongon told CNBC that Kenvue's portfolio of brands has "ample opportunity" to grow. Mongon believes product innovation ultimately makes Kenvue's brands "more relevant than ever" to consumers as they better target their needs.

☆ Johnson & Johnson's consumer health unit Kenvue started trading. What it means for J&J shareholders like us
▼ + stars: | 2023-05-05 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +9 min

For now, it's not exactly clear how J & J will go about the second step of this divestiture. In this scenario, we would have the option to relinquish some, all or none of our J & J shares. In fact, our optimism around the breakup was a big reason we bought into J & J nearly a year ago . J & J continues to argue against claims that its baby powder and other talc products caused cancer lack merit. "Look at it as a whole company today, knowing that [roughly] 10% doesn't belong to J & J," explained Cantor Fitzgerald analyst Louise Chen, who has a buy rating and maintains a $215 price target on J & J.

☆ J&J's Kenvue eyes $47 billion valuation in biggest US IPO since 2021
▼ + stars: | 2023-05-04 | by ( ) www.reuters.com time to read: +1 min

[1/2] The company logo for Kenvue Inc. Johnson & Johnson's consumer-health business, is displayed on a screen during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. REUTERS/Brendan McDermidMay 4 (Reuters) - Johnson & Johnson's (JNJ.N) consumer health unit Kenvue Inc (KVUE.N) was set to fetch a valuation of about $47 billion on Thursday, in what would be the biggest U.S. initial public offering since late 2021. Shares, priced at $22 apiece by Kenvue, were indicated to open nearly 14% above their offer price on the New York Stock Exchange. While the Kenvue deal is the largest IPO to launch since electric-vehicle maker Rivian Automotive Inc (RIVN.O) listed its shares on the Nasdaq in late 2021, deal advisers have warned that equity capital markets may not recover in a meaningful way any time soon. Reporting by Manya Saini and Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta and Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

☆ J&J's consumer health spinoff Kenvue opens at $25.53, a 16% jump, in public market debut
▼ + stars: | 2023-05-04 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Thibaut Mongon, CEO and Paul Ruh CFO of Kenvue Inc. a Johnson & Johnson's consumer-health business, pose together during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. Johnson & Johnson 's consumer health spinoff Kenvue jumped 16% in its market debut on the New York Stock Exchange Thursday, marking the biggest U.S. IPO in more than a year. Kenvue sold 172.8 million shares in an upsized deal that raised about $3.8 billion and valued the company at roughly $41 billion. "Millions of consumers around the world this morning wake up with a Kenvue product in their home," CEO Thibaut Mongon, told CNBC's "Squawk on the Street" Thursday morning ahead of the stock's debut. Mongon previously served as J&J's executive vice president and worldwide chair of consumer health.

☆ Don't expect an IPO market revival in these conditions even as J&J's Kenvue breaks drought
▼ + stars: | 2023-05-04 | by ( Bob Pisani | ) www.cnbc.com time to read: +5 min

The health of the IPO market is dependent on many factors, but principally it boils down to: 1) the strength of the overall stock market (trending up is best), and 2) interest rates (lower is better). The IPO investor wish list: stable markets, Fed done hiking, and lower IPO prices "The most important factor for the IPO market is you need the market to hold up well," Santosh Rao, head of Research at Manhattan Venture Partners, told me. Another essential ingredient for a healthy IPO market: stable interest rates. But the IPO market hasn't seen a "normal" year in a while. High initial IPO prices have proven to be devastating to IPO investors.

☆ Jim Cramer lays out how to play the impending debt ceiling crisis
▼ + stars: | 2023-05-04 | by ( Natasha Piñon | ) www.cnbc.com time to read: +1 min

Turmoil in bank stocks may feel like a looming "train wreck" for Wall Street, but as long as the debt ceiling crisis is resolved it won't destroy the market, Jim Cramer said Thursday. "If we do rally short-term, I recommend taking some profits and then steeling yourself for the debt ceiling fiasco, and then you can buy more." The debt ceiling crisis is just one of four major hurdles Cramer sees in the market right now. But if concerns about the debt ceiling are cleared, that should pave the way for a much more upbeat market, Cramer said. It could potentially reopen the IPO window and usher in good deals, like Thursday's market debut of Johnson & Johnson 's consumer-health spinoff, Kenvue .

☆ J&J's consumer health business Kenvue is going public this week. Here's what to know
▼ + stars: | 2023-05-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson products on a shelf in a store in New York. Johnson & Johnson 's consumer health business, Kenvue, is expected to go public this week in the largest U.S. IPO in more than a year. Kenvue is expected to set an IPO price Wednesday night and start trading Thursday morning on the New York Stock Exchange under the ticker "KVUE." Kenvue would be valued at around $40 billion at the proposed share range, based on the 1.87 billion shares expected to be outstanding once the deal closes. J&J would hold nearly all of those outstanding shares, amounting to more than 1.71 billion shares, according to the prospectus.

☆ J&J's Kenvue prices upsized IPO at upper end of range to raise $3.7 bln -sources
▼ + stars: | 2023-05-03 | by ( Echo Wang | ) www.reuters.com time to read: +1 min

Kenvue defied volatile market conditions to price about 166 million shares at $22 per share, the sources said, adding that the size of the deal was upsized by about 10%. The IPO values Kenvue at about $41 billion. Kenvue had earlier said it planned to sell 151 million shares at a range of between $20 and $23 per share. Kenvue's share sale marks the biggest IPO to result from a corporate carve-out in over two decades. The IPO market has been largely frozen over the past year as stock-market volatility and economic uncertainty have put off many hopefuls.

☆ Johnson & Johnson's Kenvue spinoff revives hope that the IPO market may be opening
▼ + stars: | 2023-04-25 | by ( Bob Pisani | ) www.cnbc.com time to read: +4 min

The news that Johnson & Johnson had finally begun a roadshow for its long-awaited Kenvue spinoff elicited some satisfaction among IPO watchers. "The investor base is very familiar with the products," Matthew Kennedy, IPO market strategist at Renaissance Capital told me. In the 10 years from 2013 to 2022, about $55 billion was raised on average each year in the IPO market. But in 2022, the IPO market cratered. "Hopefully this will be a more rational IPO market," Rao told me, noting that IPOs have typically underperformed the market because of high initial prices.

☆ Johnson & Johnson to price shares of consumer spinoff Kenvue at $20 to $23 in IPO
▼ + stars: | 2023-04-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson will price shares of its consumer-health spinoff Kenvue at $20 to $23 in an initial public offering later this year, the company said in a regulatory filing Monday. J&J said it launched a roadshow for the IPO of more than 151 million shares of common stock. Kenvue estimates the IPO will generate net proceeds of around $3.15 million, the filing said. Kenvue expects to grant underwriters a 30-day option to purchase up to an additional 22.6 million shares of stock to cover any over-allotments, according to the filing. The company noted it will own 1.7 billion shares of Kenvue's common stock after the IPO, representing 91.9% of the spinoff's total shares.

☆ Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report says
▼ + stars: | 2023-04-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Johnson & Johnson 's consumer health business is valued at $40 billion ahead of its initial public offering later this year, according to a report by The Wall Street Journal. The soon-to-be spinoff Kenvue aims to raise $3.5 billion or more in the offering, people familiar with the matter told the Journal. Kenvue plans to meet with prospective investors as early as Monday, the sources told the Journal. When asked about the Journal's report, J&J spokesperson Tesia Williams told CNBC, "Unfortunately, I do not have any information to provide." J&J still faces thousands of allegations that its talc baby powder and other talc products caused cancer.

Search resuls for: "Kenvue's"

20 mentions found